title: Effect of short-term standard therapeutic regimens on neuropeptide Y and adipose tissue hormones in overweight insulin-resistant women with polycystic ovary syndrome.
abstract: OBJECTIVE
  The study was aimed at elucidating the influence of a 3-month treatment with routine therapeutic regimens--oral hormonal contraceptives (OHC) with antiandrogenic activity (a standard combination of ethynil estradiol 35 microg plus cyproterone acetate 2 mg) in combination with insulin sensitizing agents--metformin (Group I) and rosiglitazone (Group II) on adipose tissue hormones and hypothalamic neuropeptide Y (NPY) in women with polycystic ovary syndrome.
  
  
  METHODS
  The study included 66 overweight insulin resistant women with PCOS according to the recent ESHRE-ASRM criteria randomized into 2 age-matched therapeutic groups.
  
  
  RESULTS
  Significant decrease of leptin (P < 0.01; P = 0.001, resp.), resistin (P < 0.01; P < 0.01, resp.), tumour necrosis factor alpha (TNF alpha) (P = 0.001; P < 0.001, resp.), and NPY (P < 0.05; P < 0.001, resp.) was observed in both groups after treatment. These findings were in parallel with a significant decrease in the anthropometric parameters of body weight in the metformin group only. No significant changes in hormonal characteristics of the groups were found except for a significant decrease in androstenedione and DHEA-S (P < 0.05) in the metformin group and in 17-OH-progesterone (P < 0.05) in the rosiglitazone group. HDL-cholesterol rose and diastolic blood pressure fell significantly (P < 0.05) in the metformin group.
  
  
  CONCLUSIONS
  Our data suggest beneficial effects of the treatment on potential cardiovascular risk in insulin resistant PCOS women.
authors.affiliation: Clinic of Endocrinology and Metabolic Diseases, St George University Hospital, Medical University Plovdiv, Bulgaria. morbetzova@abv.bg
authors.forename: Maria M
authors.initials: MM
authors.lastname: Orbetzova
authors.forename: Blagovest K
authors.initials: BK
authors.lastname: Pehlivanov
authors.forename: Mitko M
authors.initials: MM
authors.lastname: Mitkov
authors.forename: Iliana B
authors.initials: IB
authors.lastname: Atanassova
authors.forename: Zdravko A
authors.initials: ZA
authors.lastname: Kamenov
authors.forename: Georgi B
authors.initials: GB
authors.lastname: Kolarov
authors.forename: Gencho D
authors.initials: GD
authors.lastname: Genchev
mesh_terms: D000328:Adult; D015992:Body Mass Index; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D009478:Neuropeptide Y / Q000097:blood*; D050177:Overweight / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D052243:Resistin / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D020738:Leptin; D009478:Neuropeptide Y; C499624:RETN protein, human; D052243:Resistin; D014409:Tumor Necrosis Factor-alpha